Estrogen Receptors in Prolactinomas: A Clinico-Pathological study

Pituitary

Volumn 1, Issue 2, 1999, Pages 91-98

  Kaptain, G J ^a,b   Simmons, N E ^a   Alden, T D ^a   Lopes, M B ^a   Vance, M L ^a   Laws, E R ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Adenoma; Dopamine; Estrogen; Immumohistochemistry; Pituitary; Prolactinoma

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; KI 67 ANTIGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; ARTICLE; FEMALE; HUMAN; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PATHOLOGY; PROLACTINOMA;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; PITUITARY NEOPLASMS; PROLACTINOMA; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0033289469     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009903603495     Document Type: Article

References (41)

1. Thomson JA, Davies DL, McLaren EH, Teasdale GM. Ten year follow-up of microprolactinoma treated by transsphenoidal surgery. BMJ 1994;309:1409-1410.
2. Thomson JA, Teasdale GM, Gordon D, McCruden DC, Davies DL. Treatment of presumed prolactinoma by transsphenoidal operation: early and late results. BMJ 1985;291:1550-1553.
3. Randall RV, Laws ER, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW. Transsphenoidal microsurgical treatement of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clin Proc 1983;58:108-121.
4. Gooren LJG, Assies J, Asscheman H, de Slegte R, van Kessel H. Estrogen induced prolactinoma in a man. J Clin Endocrinol Metab 1983;66:444-446.
5. Gooren LJG, Harmsen-Louman W, van Kessel H. Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction. Clin Endocrinol 1985;22:201-207.
6. Fujimoto M, Yoshino E, Mizukawa N, Hirakawa K. Spontaneous reduction in size of prolactin-producing adenoma after delivery. J Neurosurg 1985;63:973-974.
7. Holmgren U, Bergstrand G, Hagenfeldt K, Werner S. Women with prolactinoma - effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol 1986;111:452-459.
8. Kovacs K, Stefaneanu L, Ezzat S, Smyth HS. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Arch Pathol Lab Med 1994;118:562-565.
9. Panteon E, Loumaye E, Maes M, Malvaux P. Occurence of prolactinoma after estrogen treatment in a girl with constitutional tall stature. J Pediatric 1988;113:337-339.
10. Maurer RA, Notides AC. Identification of an estrogen-responsive element from the 5′-flanking region of the rat prolactin gene. Molec Cell Biol 1987;7:4247-4254.
11. Rose C, Andersen KW, Mouridsen HT, Thorpe SM, Pedersen BV, Blichert-Toft M, Rasmussen BB. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985;1:16-19.
12. Carroll RS, Zhang J, Dashner K, Sar M, McL Black P. Steroid hormone receptors in astrocytic neoplasms. Neurosurg 1995;37:496-504.
13. Fujimoto M, Yoshino E, Hirakawa K, Fujimoto J, Tamaya T. Estrogen receptors in brain tumors. Clin Neuropharmacol 1984;7:357-362.
14. Stojkovic RR, Jovancevic M, Santel DJ, Grcevic N, Gamulin S. Sex steroid receptors in intracranial tumors. Cancer 1990;65:1968-1970.
15. Friend KE, Chiou YK, Lopes MBS, Laws ER, Hughes KM, Shupnik MA. Estrogen receptor expression in human pituitary: correlation with immunohistochemistry in normal tissue, and immunohistochemistry and morphology in macroadenomas. J Clin Endocrinol Metab 1994;78: 1497-1504.
16. Pichon MF, Bression D, Peillon F, Milgrom E. Estrogen receptors in human pituitary adenomas. J Clin Endocrinol Metabol 1980;51:897-902.
17. Nakao J, Koga M, Arao M, et al. Enzyme-immunoassay for estrogen receptors in human pituitary adenomas. Acta Endocrinol (Copenh) 1989;120:233-238.
18. Stefaneanu L, Kovacs K. Immunocytochemical approach to demonstrate the estrogen receptor in human adenohypophyses and pituitary adenomas with monoclonal antibody. Med Sci Res 1988;16:449-450.
19. Barrow DL, Mizuno J, Tindall GT. Management of prolactinomas associated with very high serum prolactin levels. J Neurosug 1988;68:554-558.
20. Bevan JS, Adams CBT, Burke CW, Morton KE, Molyneux AJ, Moore RA, Esiri MM. Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumor, including pre-operative bromocriptine therapy. Clin Endocrinol 1987;26:541-556.
21. Faria MA, Tindall GT. Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. Results in 100 women with the amenorrhea-galactorrhea syndrome. J Neurosurg 1982;56:33-43.
22. Laws ER, Ebersold MJ, Piepgras DG, Abboud CF, Randall RV, Scheithauer BW. The role of surgery in the management of prolactinoma. In: MacLeod RM, Thorner MO, Scapagnini U eds. Prolactin basic and clinical correlates. Padova: Livinia Press, 1985:849-853.
23. Nelson PB, Goodman M, Maroon JC, Martinez J, Moossy J, Robinson AG. Factors in predicting outcome from operation in patients with prolactin-secreting pituitary adenomas. Neurosurg 1983;13:634-641.
24. Randall RV, Scheithauer BW, Laws ER, Abboud CF, Ebersold MJ, Kao PC. Pituitary adenomas associated with hyperprolactinemia: a clinical and immunohistochemical study of 97 patients operated on transsphenoidally. Mayo Clin Proc 1985;60:753-762.
25. Selman WR, Laws ER, Scheithauer BW, Carpenter SM. The occurrence of dural invasion in pituitary adenomas. J Neurosurg 1986;64:402-407.
26. Thapar K, Kovacs K, Scheithauer BW et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using MIB-1 antibody. Neurosurg 1996;38:99-107.
27. Wilson CB. A decade of pituitary microsurgery. The Herbert Olivecrona Lecture. J Neurosurg 1984;61:814-833.
28. Hsu S, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am Soc Clin Pathol 1981;75:816-821.
29. Shi S, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39:741-748.
30. Nichols GE, Frierson HF, Boyd JC, Hanigan MH. Automated immunohistochemical analysis for estrogen receptor status in breast cancer using monoclonal antibody CC4-5 on Ventana ES. Am J Clin Pathol 1996;106:332-338.
31. th ed. Philadelphia: J.B. Lippincott, 1994:1264-1330.
32. de Quijada M, Timmermans HAT, Lamberts SWJ. Tamoxifen suppresses both the growth of prolactin-secreting pituitary tumors and normal prolactin synthesis in the rat. J Endocrinol 1980;86:109-116.
33. de Quijada M, Timmermans HAT, Lamberts SWJ, MacLeod RM. Tamoxifen enhances the sensitivity of dispersed prolactin-secreting pituitary tumor cells to dopamine and bromocriptine. Endocrinol 1980;106:702-706.
34. Lamberts SWJ, Verleun T, Oosterom R. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinol 1982;34: 339-342.
35. Volker W, Gehring WG, Berning R, Schmidt RC, Scheider J, von zur Muhlen A. Impaired pituitary response to bromocriptine suppresion: reversal after bromocriptine plus tamoxifen. Acta Endocrinol 1982;101:491-600.
36. Breast Cancer Trials Committee. Lancet 1987;2:171-175.
37. Lloyd RV: Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland. An immunohistochemical study. Am J Pathol 1983;113:198-206.
38. Buckman MT, Peake GT, Srivastava LS. Periovulatory enhancement of spontaneous prolacin secretion in normal women. Metabolism 1980;29:753-757.
39. Franks S. Regulation of prolactin secretion by oestrogens: physiological and pathological significance. Clin Sci 1983;65:457-462.
40. Hulting AL, Werner S, Hagenfeldt K. Oral contraceptive steroids do not promote the development or growth of prolactinomas. Contracep 1983;27:69-73.
41. Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 1997;86:113-120.